Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

被引：3
|
作者：
Hill, A [1 ]
机构：
[1] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
来源：
AIDS | 2005年 / 19卷 / 17期
关键词：
D O I：
10.1097/01.aids.0000194137.73876.d5
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2054 / 2055
页数：2
相关论文
共 50 条
  • [21] LOST IN TRANSLATION: A MARKOV MODEL COST UTILITY ANALYSIS OF LOPINAVIR/RITONAVIR VS ATAZANAVIR plus RITONAVIR
    Foglia, E.
    Restelli, U.
    Bonfanti, M.
    Porazzi, E.
    Bonizzoni, E.
    Bonfanti, P.
    Rizzardini, G.
    Ricci, E.
    Casartelli, L.
    Croce, D.
    VALUE IN HEALTH, 2011, 14 (07) : A281 - A281
  • [22] Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
    Pulido, Federico
    Arribas, Jose R.
    Delgado, Rafael
    Cabrero, Esther
    Gonzalez-Garcia, Juan
    Perez-Elias, Maria J.
    Arranz, Alberto
    Portilla, Joaquin
    Pasquau, Juan
    Iribarren, Jose A.
    Rubio, Rafael
    Norton, Michael
    AIDS, 2008, 22 (02) : F1 - F9
  • [23] Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens
    Castagna, Antonella
    Galli, Laura
    Gianotti, Nicola
    Torti, Carlo
    Antinori, Andrea
    Maserati, Renato
    Monforte, Antonella d'Arminio
    Quiros-Roldan, Eugenia
    Salpietro, Stefania
    Lazzarin, Adriano
    NEW MICROBIOLOGICA, 2013, 36 (03): : 239 - 249
  • [24] Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV outpatient study (HOPS) cohort
    Buchacz, Kate
    Young, Benjamin
    Baker, Rose K.
    Moorman, Anne
    Chmiel, Joan S.
    Wood, Kathy C.
    Brooks, John T.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2006, 43 (05) : 626 - 628
  • [25] Atazanavir and lopinavir/ritonavir:: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen
    Ribera, E
    Azuaje, C
    Lopez, RM
    Diaz, M
    Feijoo, M
    Pou, L
    Crespo, M
    Curran, A
    Ocaña, I
    Pahissa, A
    AIDS, 2006, 20 (08) : 1131 - 1139
  • [26] Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study
    Zhu, Li
    Liao, Shanmei
    Child, Michael
    Zhang, Jenny
    Persson, Anna
    Sevinsky, Heather
    Eley, Timothy
    Xu, Xiaohui
    Krystal, Mark
    Farajallah, Awny
    McGrath, Donnie
    Molina, Jean-Michel
    Bertz, Richard
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2012, 67 (02) : 465 - 468
  • [27] Saquinavir plus lopinavir/ritonavir versus amprenavir plus lopinavir/ritonavir for treating highly resistant patients in Brazil
    Tenore, Simone
    Ferreira, Paulo A.
    Diaz, Ricardo Sobhie
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2008, 47 (04) : 526 - 528
  • [28] Comparison of different lopinavir/ritonavir resistance algorithms
    Chantret, M
    Chapplain, JM
    Kerriguy, N
    Guist'hau, O
    Gicquel, J
    Arvieux, C
    Michelet, C
    Ruffault, A
    ANTIVIRAL THERAPY, 2002, 7 : S123 - S123
  • [29] Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients
    Waters, Laura J.
    Moyle, Graeme
    Bonora, Stefano
    D'Avolio, Antonio
    Else, Laura
    Mandalia, Sundhiya
    Pozniak, Anton
    Nelson, Mark
    Gazzard, Brian
    Back, David
    Boffito, Marta
    ANTIVIRAL THERAPY, 2007, 12 (05) : 825 - 830
  • [30] Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients
    Kalantari, Saeed
    Fard, Soheil R.
    Maleki, Donya
    Taher, Mahshid T.
    Yassin, Zeynab
    Alimohamadi, Yousef
    Minaeian, Sara
    JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (12) : 6557 - 6565
12345